Tag: MONOGRAPH

  • Cariprazine

    Plain-language summaryIntrigue 69 / 100

    Cariprazine (Vraylar) is a Hungarian-developed dopamine D2/D3 partial agonist from Gedeon Richter and AbbVie, approved by the FDA in 2015. It is structurally and mechanistically related to aripiprazole, but with a meaningful refinement: it preferentially binds the D3 receptor over D2 by roughly 6-fold. D3 receptors are concentrated in brain regions involved in motivation and cognition, which gives cariprazine a unique profile useful for the negative symptoms of schizophrenia (apathy, social withdrawal, cognitive blunting) where most antipsychotics fail. It is approved for schizophrenia, bipolar mania, bipolar depression, and as add-on for major depression. The very long half-lives of its active metabolites mean it takes weeks to reach steady state and weeks to wash out. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist atypical antipsychotic

    A D3-preferring dopamine receptor partial agonist developed by Gedeon Richter as an atypical antipsychotic, distinguished from aripiprazole and brexpiprazole by subnanomolar D3 affinity exceeding that of endogenous dopamine and by the generation of two pharmacologically active long-lived metabolites that collectively produce an effective half-life of approximately one week.

    Abstract

    Cariprazine (RGH-188; marketed as Vraylar) is a dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist approved by the United States Food and Drug Administration for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, depressive episodes associated with bipolar I disorder (bipolar depression), and adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant therapy. The compound was discovered by Gedeon Richter Plc. in Budapest, Hungary, first synthesized in 2002, and advanced through clinical development in partnership with Forest Laboratories (subsequently Actavis, Allergan, and AbbVie), receiving initial FDA approval in September 2015 and European Medicines Agency approval in 2017 under the trade name Reagila. Cariprazine is pharmacologically distinguished from the other clinically marketed dopamine partial agonist antipsychotics (aripiprazole, brexpiprazole) by its exceptionally high affinity for the dopamine D3 receptor (Ki approximately 0.085 nM), which exceeds the affinity of endogenous dopamine for the same receptor and produces a degree of D3 occupancy at clinical doses that is not achievable by any other marketed antipsychotic. The D3-preferring profile, with approximately 6- to 8-fold selectivity over D2, is hypothesized to underwrite the compound’s differentiated efficacy on negative symptoms of schizophrenia, cognitive impairment, anhedonia, and motivational deficits, domains that are poorly served by D2-predominant antipsychotic pharmacology. Cariprazine additionally binds the serotonin 5-HT1A receptor as a partial agonist (Ki approximately 2.6 nM) and the serotonin 5-HT2B receptor with high affinity (Ki approximately 0.6 nM), while showing low affinity for histamine H1, muscarinic, and alpha-1 adrenergic receptors, a selectivity profile that predicts low sedation, low anticholinergic burden, and low orthostatic hypotension relative to the broader atypical antipsychotic class.

    The pharmacokinetic profile of cariprazine is dominated by its two major active metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR), both of which possess pharmacological activity comparable to the parent compound at D3, D2, and 5-HT1A receptors. The parent compound has a half-life of 2 to 4 days; DCAR has a half-life of 1 to 2 days; and DDCAR, the predominant circulating active species at steady state, has a half-life of 1 to 3 weeks. The effective half-life of total active moieties is approximately 1 week, with steady-state equilibrium achieved at approximately 3 weeks of daily dosing. This pharmacokinetic profile has important implications for dose titration (clinical effects may lag dose changes by days to weeks), for drug-drug interactions (strong CYP3A4 inhibitors require dose reduction; strong CYP3A4 inducers are contraindicated), and for washout after discontinuation (pharmacological activity persists for several weeks).

    The clinical evidence base comprises multiple Phase 2 and Phase 3 randomized controlled trials across four approved indications, a head-to-head Phase 3b trial against risperidone for predominant negative symptoms of schizophrenia (demonstrating statistically significant superiority on the PANSS factor score for negative symptoms), and relapse prevention data in schizophrenia. The adverse-event profile is characterized by akathisia and extrapyramidal symptoms as the most common treatment-emergent adverse events (dose-dependent, typically mild to moderate), with a comparatively favorable metabolic profile (minimal weight gain, negligible effects on glucose and lipid parameters) and low prolactin elevation relative to other atypical antipsychotics. This monograph reviews the chemistry, receptor pharmacology, pharmacokinetics, preclinical pharmacology, clinical evidence across all approved and investigational indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five alternative atypical antipsychotic agents against cariprazine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1503Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Arimistane

    Steroidal mechanism-based (suicide) aromatase inhibitor derived from the 7-oxo-dehydroepiandrosterone metabolic pathway

    A naturally occurring androstadienedione metabolite of 7-keto-DHEA that functions as an irreversible steroidal aromatase inactivator, distinguished from pharmaceutical aromatase inhibitors by its endogenous biosynthetic origin and concurrent reported activity on cortisol regulation through competitive inhibition of 11-beta-hydroxysteroid dehydrogenase type 1.

    Abstract

    Androsta-3,5-diene-7,17-dione, marketed and commonly known as Arimistane, is a steroidal mechanism-based irreversible inhibitor of aromatase (cytochrome P450 19A1, CYP19A1) that occupies a distinctive position in the landscape of estrogen-modulating compounds. Structurally, it is an androstadienedione bearing conjugated 3,5-diene unsaturation in the A/B ring system and a 7-oxo group on the B ring, with the characteristic 17-ketone of the androstane series. The compound is a downstream metabolite of 7-keto-dehydroepiandrosterone (7-keto-DHEA, 3-beta-hydroxyandrost-5-ene-7,17-dione), itself produced from dehydroepiandrosterone (DHEA) by hepatic cytochrome P450 7B1 (CYP7B1) or CYP3A-mediated 7-alpha-hydroxylation followed by 11-beta-hydroxysteroid dehydrogenase (11-beta-HSD) oxidation at the 7-position and subsequent dehydration. This endogenous biosynthetic origin distinguishes Arimistane from fully synthetic aromatase inhibitors such as exemestane, letrozole, and anastrozole.

    The aromatase-inhibitory mechanism of Arimistane belongs to the type I (steroidal, mechanism-based) class characterized by Covey and colleagues in the early 1980s for the structurally related androst-5-ene-7,17-dione series [1, 2]. Mechanism-based inhibition proceeds through initial competitive binding of the steroidal inhibitor to the substrate-binding pocket of aromatase, followed by enzyme-catalyzed oxidative processing that generates a reactive intermediate capable of forming a covalent bond with amino acid residues at or near the active site. The covalent modification permanently inactivates the enzyme molecule; restoration of aromatase activity requires de novo protein synthesis rather than simple inhibitor dissociation. This irreversible (“suicide”) mechanism produces sustained estrogen suppression that persists beyond the plasma residence time of the parent compound, a pharmacodynamic feature shared with the clinically approved steroidal aromatase inactivator exemestane.

    Beyond aromatase inhibition, Arimistane has been reported to modulate cortisol metabolism through competitive inhibition of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1), the microsomal enzyme that catalyzes the reduction of cortisone to the biologically active glucocorticoid cortisol in liver, adipose tissue, and central nervous system. This activity, attributed to the 7-oxo-androstane structural motif shared with 7-keto-DHEA and its metabolites, is proposed to reduce local cortisol regeneration without affecting adrenal cortisol synthesis directly. The dual aromatase-inhibitory and cortisol-modulatory profile has driven interest in Arimistane within the bodybuilding and sports-performance supplement industry, where the compound has been marketed as a post-cycle therapy agent and estrogen-control supplement.

    The regulatory status of Arimistane is restrictive. The United States Food and Drug Administration (FDA) has determined that androsta-3,5-diene-7,17-dione does not meet the statutory definition of a dietary ingredient under section 201(ff)(1) of the Federal Food, Drug, and Cosmetic Act, and has issued multiple warning letters to supplement manufacturers marketing products containing the compound [3]. The World Anti-Doping Agency (WADA) added Arimistane to the Prohibited List in 2017 under the category of hormone and metabolic modulators (class S4), specifically as an aromatase inhibitor [4]. The compound is not approved as a pharmaceutical in any jurisdiction.

    The clinical evidence base for Arimistane is sparse relative to pharmaceutical aromatase inhibitors. No registration-quality clinical trials have been conducted. Published human data are limited to manufacturer-sponsored tolerability assessments and analytical chemistry studies characterizing the compound as a urinary metabolite of 7-keto-DHEA in anti-doping contexts [5]. The pharmacological characterization rests principally on in vitro aromatase inhibition assays, structure-activity relationship inference from the broader androstene-7,17-dione series studied by Covey, Brodie, and colleagues in the 1980s and 1990s [1, 2, 6], and extrapolation from the more extensive clinical pharmacology of the structurally related steroidal aromatase inactivator exemestane. This monograph reviews the chemistry, biosynthetic origin, mechanism of aromatase inactivation, reported pharmacokinetics, preclinical and clinical evidence, sourcing and quality considerations, stack interactions, adverse-event signal, and a comparative assessment of Arimistane against five alternative aromatase-modulating compounds on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1539Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • KW-6356

    Selective non-xanthine adenosine A2A receptor antagonist and inverse agonist

    A second-generation, non-xanthine adenosine A2A receptor antagonist and inverse agonist developed by Kyowa Kirin as a successor to istradefylline for the treatment of Parkinson’s disease, distinguished by insurmountable antagonism, inverse agonist activity, and approximately 100-fold greater receptor affinity than the first-generation A2A antagonist class.

    Abstract

    KW-6356 (sipagladenant; CAS 858979-50-7) is a selective, non-xanthine adenosine A2A receptor antagonist and inverse agonist developed by Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin) as a next-generation successor to istradefylline (NOURIANZ/NOURIAST) for the treatment of motor and non-motor symptoms of Parkinson’s disease. The compound exhibits approximately 100-fold greater binding affinity for the human adenosine A2A receptor than istradefylline (pKi 9.93 versus approximately 7.9), with a Kd of 0.13 nM and a Ki of 0.12 nM at the human A2A receptor, and demonstrates greater than 100-fold selectivity over the A1, A2B, and A3 adenosine receptor subtypes [1]. In contrast to istradefylline, which acts as a surmountable antagonist, KW-6356 exhibits two pharmacologically distinct properties: insurmountable antagonism (the capacity to suppress receptor signaling in a manner that cannot be fully overcome by increasing agonist concentration) and inverse agonism (the capacity to reduce constitutive, agonist-independent receptor activity below basal levels). X-ray crystallography of the KW-6356-bound human A2A receptor at 2.30 angstrom resolution (PDB: 8GNE) has revealed that interactions with His250 (position 6.52) and Trp246 (position 6.48) are essential for the inverse agonist activity, while deep orthosteric pocket contacts and stabilization of the extracellular loop conformation contribute to the insurmountable antagonism [1].

    The clinical development program evaluated KW-6356 in two pivotal Phase 2 studies in Japanese Parkinson’s disease populations. A Phase 2a randomized, double-blind, placebo-controlled monotherapy trial in 168 patients with early, untreated Parkinson’s disease demonstrated that once-daily oral KW-6356 at 3 mg and 6 mg produced improvements in MDS-UPDRS Part III motor scores (least-squares mean changes from baseline to week 12 of -5.37 and -4.76, respectively, versus -3.14 for placebo) [2]. A subsequent Phase 2b randomized, double-blind, placebo-controlled adjunct-to-levodopa trial in 503 patients with levodopa-treated Parkinson’s disease demonstrated statistically significant improvements in MDS-UPDRS Part III motor scores at both 3 mg (p = 0.006 versus placebo) and 6 mg (p = 0.049 versus placebo), with additional reductions in mean daily OFF time in the key secondary endpoint and improvements on the PD Sleep Scale-2 in post-hoc analysis [3, 4]. Preclinical pharmacology in MPTP-treated common marmosets confirmed dose-dependent reversal of motor disability at oral doses up to 1 mg/kg, with anti-parkinsonian activity significantly greater than that of istradefylline and a low risk of inducing dyskinesia [5, 6].

    Pharmacokinetics in healthy volunteers demonstrated linear exposure after single oral doses of 1 to 60 mg, with a mean terminal elimination half-life of 18.4 to 43.1 hours (mean approximately 22.9 hours), a time to peak plasma concentration of 0.75 to 3 hours, and an active metabolite (M6) with comparable A2A antagonist and inverse agonist potency and an elimination half-life of approximately 4.34 hours [7, 8]. Population pharmacokinetic modeling identified food status, baseline serum albumin, and baseline body weight as covariates, but none had clinically meaningful impact on KW-6356 or M6 exposure [8]. The compound was well tolerated in Phase 1 studies at single doses up to 60 mg and multiple doses up to 24 mg once daily for 14 days, with no clinically meaningful changes in vital signs, body weight, laboratory parameters, or electrocardiograms [7]. The most common adverse events in the Phase 2a monotherapy trial were constipation (7.3 percent at 3 mg, 6.9 percent at 6 mg) and nasopharyngitis (7.3 percent at 3 mg, 8.6 percent at 6 mg) [2].

    Despite positive proof-of-concept results across both monotherapy and adjunct-to-levodopa settings, Kyowa Kirin announced discontinuation of the KW-6356 development program in July 2022, citing evaluation of the global regulatory landscape, development hurdles, and timelines for potential market entry rather than efficacy or safety concerns [9]. The discontinuation followed Lundbeck’s earlier decision to return ex-Asia development rights to Kyowa Kirin. No Phase 3 trials were initiated. This monograph documents the chemistry, structural pharmacology, receptor binding and selectivity profile, preclinical and clinical evidence base, pharmacokinetics, safety signal, and a comparative assessment of KW-6356 against five adenosine A2A receptor antagonists on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1527Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Sildenafil

    Selective phosphodiesterase type 5 (PDE5) inhibitor of the pyrazolopyrimidinone structural class

    A pyrazolopyrimidinone-based cyclic GMP-specific phosphodiesterase type 5 inhibitor originally developed at Pfizer as an antianginal agent, repositioned as the first oral pharmacotherapy for erectile dysfunction and subsequently approved for pulmonary arterial hypertension, with an expanding preclinical evidence base in cardioprotection, neuroprotection, and vascular inflammation.

    Abstract

    Sildenafil (UK-92480) is a potent, competitive, and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the enzyme principally responsible for hydrolytic degradation of cGMP in vascular smooth muscle, the corpus cavernosum, and the pulmonary vasculature. The compound was synthesized at the Pfizer Global Research and Development laboratories in Sandwich, Kent, United Kingdom in 1989 as part of a medicinal chemistry program targeting selective PDE5 inhibition for the treatment of angina pectoris and hypertension. Phase I clinical trials revealed limited antianginal efficacy but a pronounced and reproducible effect on penile erection, prompting repositioning toward erectile dysfunction. Sildenafil received United States Food and Drug Administration (FDA) approval on 27 March 1998 as the first oral pharmacotherapy for erectile dysfunction (marketed as Viagra) and subsequently received FDA approval in June 2005 for the treatment of World Health Organization Group I pulmonary arterial hypertension (marketed as Revatio).

    The pharmacological mechanism is inhibition of PDE5 at the catalytic site with an IC50 of approximately 3.5 nanomolar and selectivity over PDE1 through PDE4 of 80- to 19,000-fold, with approximately 10-fold selectivity over the structurally related retinal PDE6, the latter accounting for the dose-dependent visual disturbances observed clinically [1, 2]. PDE5 inhibition potentiates the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cGMP signaling cascade: in tissues where NO release occurs (penile corpus cavernosum during sexual stimulation, pulmonary vascular endothelium), sildenafil amplifies the downstream smooth muscle relaxation by preventing cGMP breakdown. The compound does not directly initiate smooth muscle relaxation in the absence of NO signaling, a pharmacological distinction that differentiates PDE5 inhibitors from direct NO donors and from soluble guanylyl cyclase stimulators.

    Pharmacokinetics are characterized by rapid oral absorption (time to peak plasma concentration approximately 60 minutes under fasting conditions), moderate absolute oral bioavailability of approximately 41 percent (limited by hepatic first-pass metabolism), a plasma elimination half-life of approximately 3 to 5 hours, and high plasma protein binding of approximately 96 percent [3, 4]. Metabolism is predominantly hepatic via cytochrome P450 3A4 (CYP3A4, major pathway) and CYP2C9 (minor pathway), producing the active N-desmethyl metabolite (UK-103,320) that retains approximately 50 percent of the parent compound potency at PDE5 and has a similar terminal half-life [3]. The CYP3A4 dependence creates clinically significant drug-drug interactions with strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, erythromycin), which can elevate sildenafil plasma concentrations by 3- to 11-fold.

    The clinical evidence base spans two FDA-approved indications (erectile dysfunction and pulmonary arterial hypertension) and multiple investigational applications including Raynaud phenomenon, heart failure, altitude sickness, and neuroprotection. The SUPER-1 trial in 278 patients with pulmonary arterial hypertension demonstrated significant improvement in six-minute walk distance across all sildenafil dose groups (20, 40, and 80 mg three times daily) compared to placebo [5]. A 2024 dose-ranging trial by Hoeper et al. further demonstrated dose-dependent benefit, with the 80 mg three times daily group achieving a median gain of 52 meters in six-minute walk distance [6]. Preclinical pharmacology has established cardioprotective effects against ischemia-reperfusion injury through mitochondrial ATP-sensitive potassium channel opening, neuroprotective effects in rodent stroke and neurodegeneration models through cGMP-mediated anti-apoptotic signaling, and anti-inflammatory effects through suppression of NF-kappaB-driven cytokine release.

    The compound is well tolerated at approved doses. Principal adverse events are headache (16 percent), flushing (10 percent), dyspepsia (7 percent), nasal congestion (4 percent), and dose-dependent visual disturbances (chromatopsia, increased light sensitivity) reflecting PDE6 cross-inhibition in retinal photoreceptors [7]. The critical safety concern is the absolute contraindication with organic nitrates and nitric oxide donors, where co-administration produces synergistic and potentially fatal hypotension through additive cGMP-mediated vasodilation [8]. This monograph reviews the chemistry, synthesis, and structural pharmacology of sildenafil; the molecular mechanism across PDE isoforms; comprehensive human pharmacokinetics; the clinical evidence base across approved and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five PDE5 inhibitor and vasodilator alternatives against sildenafil on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1556Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Clenbuterol

    Selective beta-2 adrenergic receptor agonist with anabolic, lipolytic, and bronchodilatory activity

    A long-acting phenylaminoethanol beta-2 adrenoceptor agonist developed at Boehringer Ingelheim as a bronchodilator, distinguished from other sympathomimetic beta-agonists by exceptional oral bioavailability, a prolonged elimination half-life of 25 to 39 hours, and potent repartitioning activity on skeletal muscle and adipose tissue that has driven extensive preclinical and clinical investigation in muscle-wasting disorders, body composition, and neuromuscular disease.

    Abstract

    Clenbuterol (4-amino-alpha-[[(1,1-dimethylethyl)amino]methyl]-3,5-dichlorobenzyl alcohol; NAB 365) is a selective, long-acting beta-2 adrenergic receptor agonist originally synthesized in 1967 at the Thomae research facility of Boehringer Ingelheim in Biberach, Germany, and approved in 1976 in that country for the treatment of reversible airway obstruction in asthma and chronic obstructive pulmonary disease. The compound acts through stimulation of the beta-2 adrenoceptor, a seven-transmembrane G-protein-coupled receptor that activates adenylyl cyclase, elevates intracellular cyclic adenosine monophosphate, and engages protein kinase A signaling cascades in airway smooth muscle, skeletal muscle, adipose tissue, and hepatocytes. In airway smooth muscle the principal consequence is bronchodilation; in skeletal muscle and adipose tissue the consequences are protein accretion and lipolysis, respectively, producing a body-composition repartitioning effect that has generated an extensive preclinical and applied research literature spanning livestock science, sports pharmacology, and clinical investigation in muscle-wasting disease.

    Pharmacokinetics in humans are characterized by rapid oral absorption (bioavailability approximately 70 to 80 percent), minimal hepatic first-pass metabolism, a prolonged terminal elimination half-life of 25 to 39 hours (substantially longer than the structurally related short-acting beta-2 agonists salbutamol and terbutaline), and predominant renal excretion of unchanged drug. The extended half-life supports once- or twice-daily oral dosing and produces measurable plasma accumulation on chronic administration, reaching steady state in approximately 4 days. Five minor metabolites have been identified in human and animal studies, none with significant pharmacological activity at the beta-2 receptor.

    The compound is approved for human bronchospastic indications in multiple European and Latin American jurisdictions but has never received approval from the United States Food and Drug Administration for human use. In the United States, clenbuterol hydrochloride is approved solely for veterinary use as Ventipulmin Syrup (Boehringer Ingelheim Vetmedica) for the management of airway obstruction in horses, under a New Animal Drug Application approved by the FDA in 1998. The compound is classified as a prohibited substance under the World Anti-Doping Agency Prohibited List (category S1.2, other anabolic agents) and is banned in competition and out-of-competition in all sports under the WADA Code. Its use as a growth-promoting agent in food-producing animals is prohibited in the European Union, the United States, and China, though enforcement challenges have produced recurring food-safety incidents.

    Beyond the registered bronchodilator indication, the principal research applications of clenbuterol are in neuromuscular disease, where pilot and open-label clinical trials have demonstrated safety and preliminary efficacy signals in spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, and spinal muscular atrophy; in skeletal muscle physiology, where the compound is the reference beta-2 agonist for studying adrenergic regulation of protein synthesis, proteolysis, and fiber-type transitions; and in cardiac biology, where the compound has been studied as a bridge-to-recovery adjunct in patients with heart failure supported by left ventricular assist devices. The cardiac research application is notable given the concurrent identification of dose-dependent myocardial toxicity in animal models and in clinical case reports of supratherapeutic use, producing a narrow therapeutic index for cardiac applications that remains an active area of investigation.

    This monograph reviews the chemistry, synthesis, and stereochemistry of clenbuterol; the receptor pharmacology and downstream signaling; the comprehensive human pharmacokinetic record; preclinical pharmacology across muscle, adipose, and cardiac tissue; the clinical evidence base across bronchospastic, neuromuscular, cardiac, and body-composition indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal including cardiac toxicity; and a structured comparative assessment of five alternative beta-2 adrenergic agonists against clenbuterol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1533Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • L-Carnitine

    Endogenous quaternary ammonium compound functioning as an obligate cofactor in mitochondrial long-chain fatty acid beta-oxidation via the carnitine palmitoyltransferase shuttle system

    A conditionally essential nutrient and FDA-approved pharmaceutical (levocarnitine) that mediates the translocation of long-chain fatty acyl groups across the inner mitochondrial membrane, with clinical applications spanning primary and secondary carnitine deficiency, cardiovascular secondary prevention, hemodialysis support, exercise performance, male reproductive health, and neuroprotection.

    Abstract

    L-Carnitine (levocarnitine) is a naturally occurring, water-soluble quaternary ammonium compound biosynthesized from the amino acids lysine and methionine in liver, kidney, and brain, and obtained exogenously from dietary sources (principally red meat and dairy products) and from pharmaceutical or nutraceutical supplementation. The compound is an obligate cofactor for the carnitine palmitoyltransferase (CPT) shuttle system, the sole mechanism by which long-chain fatty acyl-coenzyme A esters cross the inner mitochondrial membrane to undergo beta-oxidation. In the absence of adequate carnitine, mitochondrial long-chain fatty acid oxidation is impaired, producing the metabolic phenotype of primary systemic carnitine deficiency: hypoketotic hypoglycemia, cardiomyopathy, skeletal myopathy, and hepatic encephalopathy. The compound was first isolated from vertebrate muscle extract by Gulewitsch and Krimberg in 1905, structurally characterized as beta-hydroxy-gamma-trimethylaminobutyric acid by Tomita and Sendju in 1927, identified as the insect growth factor vitamin BT by Fraenkel and colleagues in the 1950s, and functionally linked to fatty acid oxidation by Fritz in 1955. Its obligate role in mitochondrial bioenergetics was established through the subsequent characterization of the CPT I, carnitine-acylcarnitine translocase (CACT), and CPT II enzyme system by McGarry, Foster, Ramsay, and colleagues in the 1970s and 1980s.

    L-Carnitine is approved by the United States Food and Drug Administration as levocarnitine (Carnitor, Leadiant Biosciences) for the treatment of primary systemic carnitine deficiency and for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease undergoing maintenance hemodialysis. Pharmacokinetics are characterized by carrier-mediated intestinal absorption via the organic cation/carnitine transporter OCTN2 (SLC22A5), with oral bioavailability of 54 to 87 percent from dietary sources but only 14 to 18 percent from high-dose oral supplements owing to saturation of active transport. Renal handling is dominated by efficient tubular reabsorption (90 to 99 percent of filtered load) via OCTN2 at physiological plasma concentrations, with saturable reabsorption kinetics producing rapid urinary clearance of supraphysiological doses. Plasma elimination half-life is approximately 2 to 6 hours for exogenous doses; the endogenous total body pool (approximately 20 to 25 grams in a 70-kilogram adult) turns over slowly with an estimated whole-body half-life of 40 to 100 hours.

    Clinical evidence for supplemental L-carnitine spans multiple therapeutic domains. In cardiovascular secondary prevention, a 2013 meta-analysis of 13 controlled trials (N = 3,629) by DiNicolantonio et al. in Mayo Clinic Proceedings reported a 27 percent reduction in all-cause mortality (OR 0.73, 95% CI 0.54 to 0.99), a 65 percent reduction in ventricular arrhythmias, and a 40 percent reduction in angina development in patients following acute myocardial infarction. In chronic heart failure, a 2017 meta-analysis of 17 trials (N = 1,625) reported significant improvements in left ventricular ejection fraction (+4.14%), stroke volume (+8.21 mL), and cardiac output (+0.88 L/min). In hemodialysis populations, Cochrane and systematic reviews have reported potential benefits for anemia, C-reactive protein reduction, and intradialytic hypotension, though evidence quality remains low to moderate. In exercise physiology, systematic reviews report benefits of 1 to 4 grams daily on VO2max, peak power output, and lactate reduction, with effect sizes dependent on dosing duration and exercise modality. In male reproductive health, meta-analyses report significant improvements in sperm motility and morphology with 1 to 3 grams daily for 3 to 6 months, though pregnancy rate improvements have not been consistently demonstrated. Acetyl-L-carnitine, a physiological ester derivative, has demonstrated efficacy in randomized controlled trials for diabetic peripheral neuropathy, with significant pain reduction and nerve fiber regeneration.

    A safety consideration of growing importance is the gut microbial conversion of L-carnitine to trimethylamine (TMA), which undergoes hepatic oxidation by flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO), a metabolite epidemiologically associated with increased atherosclerotic cardiovascular disease risk. The TMAO pathway is diet-dependent and microbiome-dependent, with omnivorous individuals producing substantially more TMAO from carnitine challenge than vegetarians or vegans. This monograph reviews the chemistry, biosynthesis, and transport of L-carnitine; the carnitine shuttle mechanism in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal including the TMAO pathway; and a comparative assessment of five mitochondrial bioenergetic support compounds against L-carnitine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1516Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Primobolan

    Synthetic androstane anabolic-androgenic steroid; 1-methyl dihydrotestosterone derivative with moderate androgen receptor agonism

    A non-17-alpha-alkylated dihydrotestosterone derivative developed by Squibb and Schering for refractory anemia and catabolic wasting, distinguished from other anabolic-androgenic steroids by its favorable hepatic safety profile, absence of aromatization, and moderate anabolic-to-androgenic dissociation.

    Abstract

    Primobolan is the trade name for metenolone (also rendered methenolone), a synthetic androstane steroid derived from dihydrotestosterone (DHT) by introduction of a 1-methyl group and a 1,2-double bond into the A-ring of the 5-alpha-reduced androstane nucleus. The compound was first synthesized in 1960 and introduced for clinical use in 1961 by Squibb Pharmaceuticals in the United States (as Nibal and Nibal Depot) and by Schering AG in West Germany (as Primobolan and Primobolan Depot). Two ester prodrug forms are manufactured: metenolone acetate (CAS 434-05-9), the oral preparation with a molecular weight of 344.50 g/mol, and metenolone enanthate (CAS 303-42-4), the intramuscular depot preparation with a molecular weight of 414.63 g/mol. Both esters undergo hydrolysis in vivo to release the parent steroid metenolone (CAS 153-00-4; molecular formula C20H30O2; molecular weight 302.46 g/mol), which binds the androgen receptor with moderate affinity and produces anabolic effects in skeletal muscle, bone, and erythropoietic tissue.

    The clinical pharmacology of metenolone is defined by several characteristics that distinguish it from structurally related anabolic-androgenic steroids. First, the compound is not 17-alpha-alkylated; the 1-methyl substitution and ester conjugation confer sufficient oral bioavailability (in the acetate form) and depot duration (in the enanthate form) without the hepatotoxic liability associated with C17-alpha-alkylated steroids such as oxymetholone, stanozolol, and methandrostenolone. Second, the 1,2-double bond and the DHT-derived backbone render metenolone resistant to aromatization by the cytochrome P450 aromatase enzyme complex (CYP19A1), eliminating estrogenic side effects including gynecomastia and estrogen-mediated fluid retention. Third, metenolone exhibits a moderate anabolic-to-androgenic dissociation ratio of approximately 88:44 to 150:50 in rodent bioassays (levator ani weight gain versus ventral prostate weight gain, relative to testosterone propionate as the reference standard), placing it in the class of mildly anabolic, mildly androgenic agents alongside oxandrolone and drostanolone.

    The principal approved clinical indication was the treatment of anemia due to bone marrow failure, including aplastic anemia, myelofibrosis, and refractory cytopenias. A therapeutic trial reported by Compagno et al. (1978) in 19 consecutive patients with refractory anemia demonstrated remission in approximately 37 percent of patients with pancytopenia and variable responses across other cytopenia subtypes [1]. Additional historical indications included protein-calorie malnutrition, postoperative and post-infectious catabolic states, osteoporosis, sarcopenia, and promotion of weight gain in premature infants. The compound has been largely discontinued from clinical markets; as of the most recent monograph revision, metenolone enanthate is marketed only in Spain and Turkey (as Primobolan Depot), and metenolone acetate retains limited availability in Japan and Moldova.

    Pharmacokinetics differ substantially between the two ester forms. Metenolone acetate is rapidly absorbed after oral administration but undergoes significant first-pass hepatic metabolism, resulting in reduced oral bioavailability relative to parenteral administration; the plasma half-life of the oral form is approximately 4 to 6 hours. Metenolone enanthate, administered by intramuscular injection in an oil vehicle, provides depot release with a biological half-life of approximately 10.5 days and a duration of action of approximately 14 days. Metabolism of metenolone proceeds through hepatic mixed-function oxidases; the principal urinary metabolite is 3-alpha-hydroxy-1-methylen-5-alpha-androstan-17-one, excreted as glucuronide and sulfate conjugates. The sulfate-conjugated metabolites provide extended detection windows in anti-doping analysis, with some metabolites detectable for several weeks after a single administration. Metenolone exhibits low affinity for sex hormone-binding globulin (SHBG), approximately 16 percent of that of testosterone and 3 percent of that of DHT, resulting in a higher fraction of unbound drug in plasma.

    Adverse effects are consistent with the anabolic-androgenic steroid class but are generally milder than those of 17-alpha-alkylated compounds. Virilization in female patients (acne, hirsutism, voice deepening, clitoral enlargement, menstrual irregularity) is the principal androgenic concern. Suppression of endogenous gonadotropin secretion (luteinizing hormone and follicle-stimulating hormone) produces dose-dependent hypothalamic-pituitary-gonadal axis suppression with consequent testicular atrophy, oligospermia, and reduced endogenous testosterone production in male users. Cardiovascular effects include unfavorable shifts in the lipoprotein profile (decreased high-density lipoprotein cholesterol, increased low-density lipoprotein cholesterol), though these shifts are generally less pronounced than those produced by 17-alpha-alkylated oral steroids. Hepatotoxicity is minimal at therapeutic doses, consistent with the absence of C17-alpha-alkylation. This monograph reviews the chemistry, synthesis, and structural pharmacology of metenolone; the androgen receptor mechanism and tissue-selective pharmacodynamics; the complete pharmacokinetic profile of both ester forms; the clinical evidence base across hematologic, catabolic, and body-composition indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events; and a comparative assessment of five alternative anabolic-androgenic steroids against Primobolan on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1549Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Telmisartan

    Non-peptide angiotensin II type 1 receptor antagonist with selective partial peroxisome proliferator-activated receptor gamma agonism

    A biphenyl-benzimidazole angiotensin II receptor blocker developed at Boehringer Ingelheim, distinguished from other sartans by intrinsic partial agonist activity at the nuclear peroxisome proliferator-activated receptor gamma and downstream metabolic, anti-inflammatory, and neuroprotective activity.

    Abstract

    Telmisartan is a non-peptide, orally active antagonist of the angiotensin II type 1 receptor (AT1R) and a selective partial agonist of the nuclear peroxisome proliferator-activated receptor gamma (PPARgamma), approved by the United States Food and Drug Administration in 1998 for the treatment of hypertension and subsequently for cardiovascular risk reduction in patients intolerant to angiotensin-converting enzyme inhibitors. The compound is marketed as Micardis (Boehringer Ingelheim) and is available in extensive generic competition worldwide. Among the eight clinically marketed angiotensin II receptor blockers (ARBs), telmisartan is distinguished by three pharmacological and pharmacokinetic features: the longest terminal elimination half-life (approximately 24 hours), the largest volume of distribution (approximately 500 liters), and a structurally defined partial agonist interaction with PPARgamma that is not shared at clinically meaningful potency by any other marketed sartan. The PPARgamma partial agonism, first formally characterized by Benson et al. (2004) in a systematic screen of ARBs against nuclear receptor panels, produces downstream modulation of carbohydrate and lipid metabolism gene expression, reduction of insulin resistance markers, suppression of NF-kappaB-driven proinflammatory cytokine release, and enhancement of adiponectin secretion, all at concentrations achieved by the registered 80 mg oral dose [1]. These pleiotropic activities extend the pharmacological profile of telmisartan substantially beyond the hemodynamic consequences of AT1R blockade and have driven a preclinical and clinical research literature encompassing metabolic syndrome, type 2 diabetes prevention, neuroprotection, renoprotection, and anti-inflammatory applications.

    The clinical evidence base for telmisartan is anchored by two landmark randomized controlled trials. The ONTARGET trial (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; N = 25,620) demonstrated that telmisartan 80 mg daily was non-inferior to ramipril 10 mg daily on a composite cardiovascular endpoint of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure in high-risk patients, with superior tolerability and fewer treatment discontinuations [2]. The TRANSCEND trial (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease; N = 5,926) demonstrated that telmisartan modestly reduced the composite of cardiovascular death, myocardial infarction, or stroke compared with placebo in ACE-inhibitor-intolerant patients, leading to the 2009 FDA supplemental indication for cardiovascular risk reduction [3]. Additional large-scale trials include PRoFESS (Prevention Regimen for Effectively Avoiding Second Strokes; N = 20,332), which evaluated telmisartan for secondary stroke prevention, and DETAIL (Diabetics Exposed to Telmisartan and Enalapril; N = 250), which demonstrated renoprotective non-inferiority to enalapril in type 2 diabetic patients with early nephropathy.

    Pharmacokinetics are characterized by dose-dependent oral bioavailability (42 percent at 40 mg, 58 percent at 160 mg), negligible cytochrome P450-mediated metabolism (less than 3 percent of the dose is glucuronidated; the remainder is excreted unchanged in bile and feces), a terminal elimination half-life of approximately 24 hours supporting once-daily dosing, and greater than 99.5 percent plasma protein binding. The compound is poorly soluble in water but freely soluble in dimethyl sulfoxide and dimethylformamide. Telmisartan does not require dose adjustment for renal impairment but should be used with caution in severe hepatic impairment owing to the predominantly biliary elimination pathway.

    This monograph reviews the chemistry, synthesis, and structural pharmacology of telmisartan; the dual AT1R antagonist and PPARgamma partial agonist mechanism in molecular detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology across cardiovascular, metabolic, neuroprotective, and renoprotective models; the clinical evidence base across all studied indications; sourcing and quality verification considerations; reconstitution and handling for laboratory use; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five alternative ARBs (losartan, valsartan, irbesartan, olmesartan, candesartan) against telmisartan on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1557Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Vesugen

    Synthetic tripeptide bioregulator (Lys-Glu-Asp) targeting vascular endothelial gene expression through epigenetic modulation

    A Khavinson-class synthetic tripeptide bioregulator derived from vascular wall protein sequences, characterized by epigenetic modulation of endothelial proliferation markers, endothelin-1 normalization, sirtuin-1 upregulation, and neuroprotective gene regulation in preclinical aging and Alzheimer’s disease models.

    Abstract

    Vesugen (Lys-Glu-Asp; KED) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson as part of a decades-long program investigating short-chain peptide regulation of age-associated tissue decline. The compound belongs to the Khavinson class of ultrashort (two to four amino acid residue) bioregulatory peptides, a family of synthetic sequences derived from organ-specific protein fractions that are proposed to penetrate cell nuclei and modulate gene expression through direct interactions with DNA promoter regions and epigenetic regulatory mechanisms. Vesugen is the synthetic analog corresponding to the vascular-wall-derived peptide fraction originally isolated as the active component of Ventfort, a polypeptide complex extracted from bovine aortic tissue. The tripeptide sequence Lys-Glu-Asp was identified as the minimal bioactive motif responsible for the vasoprotective activity of the parent extract.

    The molecular pharmacology of Vesugen is characterized by epigenetic modulation of vascular endothelial cell function. In dissociated human endothelial cell cultures, Vesugen stimulates synthesis of the proliferation-associated protein Ki-67, the expression of which declines during cellular aging [1]. Molecular docking studies demonstrate that Vesugen binds to the promoter region of the MKI67 gene, making contact through the CATC sequence at the core promoter located between positions -14 and +12 relative to the transcription initiation site [1]. In models of atherosclerotic and restenotic endothelium in vitro, Vesugen normalizes the expression of endothelin-1, restores connexin (Cx37, Cx43) expression for intercellular communication, and increases sirtuin-1 (SIRT1) expression, implicating the compound in DNA repair and cellular longevity pathways [2, 3]. The compound also modulates expression of vascular endothelial growth factor (VEGF) and the apoptosis marker p53, contributing to a net pro-proliferative and anti-apoptotic phenotype in aged vascular endothelial cells.

    Beyond its primary vascular target, Vesugen has demonstrated neuroprotective activity in several preclinical models. The tripeptide regulates expression of cell aging and apoptosis genes (p16, p21), neuronal differentiation genes and proteins (NES, GAP43, nestin), and genes implicated in Alzheimer’s disease pathogenesis (SUMO, APOE, IGF1) [4]. In hippocampal neuron cultures exposed to amyloid-beta synaptotoxicity, Vesugen increased the number of mushroom-type dendritic spines by 20 percent [5]. Oral administration of Vesugen improved memory and attention in elderly individuals with functional central nervous system disorders in a small clinical cohort [4]. In a 32-patient clinical study of elderly individuals with chronic polymorbidity and organic brain syndrome, Vesugen demonstrated anabolic properties and improved central nervous system activity, slowing the rate of aging as measured by biological age indicators [6].

    The compound is not approved by any national regulatory authority as a pharmaceutical product. It is supplied as a research-grade synthetic peptide and as a dietary supplement (capsule form) in certain jurisdictions. The primary literature on Vesugen originates predominantly from Russian research institutions, principally the Saint Petersburg Institute of Bioregulation and Gerontology and affiliated laboratories. Independent replication by Western laboratories using contemporary structural biology and pharmacology methodologies remains limited. This monograph reviews the chemistry, proposed mechanism of action, preclinical pharmacology, limited clinical evidence, sourcing and handling considerations, and a comparative assessment against five alternative vasoprotective and geroprotective peptide candidates.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1510Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Sulforaphane

    Plain-language summaryIntrigue 72 / 100

    Sulforaphane is an isothiocyanate from broccoli sprouts that potently activates Nrf2, the master regulator of antioxidant gene expression. Has shown chemopreventive effects in cancer research and is being studied for autism spectrum disorder. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Isothiocyanate organosulfur compound and potent Nrf2 pathway activator derived from glucoraphanin in cruciferous vegetables

    A dietary isothiocyanate first isolated from broccoli at Johns Hopkins University as the most potent naturally occurring inducer of mammalian phase 2 cytoprotective enzymes, now established as a multimechanistic agent acting through Keap1-Nrf2 electrophilic signaling, NF-kappaB suppression, and histone deacetylase inhibition across chemopreventive, metabolic, neurobehavioral, and anti-inflammatory research applications.

    Abstract

    Sulforaphane (1-isothiocyanato-4-methylsulfinylbutane) is a low-molecular-weight isothiocyanate generated by myrosinase-catalyzed hydrolysis of the glucosinolate glucoraphanin, found at highest concentration in broccoli sprouts and at progressively lower concentration in mature broccoli, Brussels sprouts, cauliflower, and other cruciferous vegetables. First identified in 1992 by Paul Talalay and colleagues at the Johns Hopkins University School of Medicine as the most potent naturally occurring inducer of mammalian phase 2 detoxification enzymes, sulforaphane has become the most extensively studied dietary isothiocyanate in human pharmacology and the reference compound for nutrigenomic Nrf2 activation. The primary molecular mechanism is electrophilic modification of reactive cysteine residues on the Kelch-like ECH-associated protein 1 (Keap1) sensor, leading to stabilization and nuclear translocation of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and subsequent transcriptional upregulation of a battery of cytoprotective genes including NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), glutathione S-transferases (GSTs), and thioredoxin reductase. Sulforaphane activates Nrf2 with a potency approximately 13-fold greater than curcumin, 18-fold greater than silymarin, and over 100-fold greater than resveratrol in standardized NQO1 inducer assays. A second established mechanism is the suppression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling through inhibition of IkappaB-alpha phosphorylation and degradation, producing broad anti-inflammatory activity. A third mechanism, characterized by Myzak et al. in 2004, is inhibition of histone deacetylase (HDAC) enzymes by the mercapturic acid pathway metabolites sulforaphane-cysteine and sulforaphane-N-acetylcysteine, producing epigenetic reactivation of tumor suppressor genes including p21 and Bax. Pharmacokinetics in humans are characterized by rapid oral absorption (peak plasma concentration within 1 to 3 hours), a short elimination half-life of approximately 1.8 to 2.2 hours, extensive metabolism through the mercapturic acid (glutathione conjugation) pathway, and urinary excretion of 60 to 80 percent of administered sulforaphane equivalents within 24 hours. Oral bioavailability of free sulforaphane is approximately 70 to 80 percent, while bioavailability from the glucoraphanin precursor is approximately 10 to 40 percent depending on myrosinase activity and interindividual variation in gut microbial glucosinolate hydrolysis. Over 80 interventional clinical trials have examined sulforaphane or sulforaphane-yielding preparations in human subjects across indications including cancer chemoprevention (prostate, breast, lung, colorectal, bladder), autism spectrum disorder, type 2 diabetes, schizophrenia, chronic obstructive pulmonary disease, Helicobacter pylori infection, and air pollution detoxification. The Singh et al. (2014) randomized placebo-controlled trial in young men with moderate to severe autism spectrum disorder demonstrated substantial and reversible behavioral improvement on the Aberrant Behavior Checklist and Social Responsiveness Scale after 18 weeks of daily sulforaphane administration. The Axelsson et al. (2017) trial in obese patients with dysregulated type 2 diabetes demonstrated reduced fasting blood glucose and improved glycated hemoglobin with concentrated broccoli sprout extract. The compound is generally well tolerated; the principal adverse events are mild gastrointestinal disturbance (flatulence, bloating, loose stools). Goitrogenic potential at high doses is a theoretical concern for individuals with pre-existing thyroid dysfunction. This monograph reviews the chemistry, biosynthesis, and stereochemistry of sulforaphane; the tripartite molecular pharmacology (Keap1-Nrf2, NF-kappaB, HDAC); comprehensive human pharmacokinetics; the preclinical and clinical evidence base across chemopreventive, metabolic, neurobehavioral, and anti-inflammatory indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a comparative assessment of five alternative Nrf2-activating or cruciferous-derived cytoprotective compounds against sulforaphane on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1496Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.